PURPOSE: In vivo efficacy and safety of HPMA-based copolymers armed with doxorubicin via a spacer containing pH-sensitive linkage that can be prepared within a broad range of attached drug contents (1) was tested in murine tumor models. METHODS: Mice bearing T cell lymphoma EL4 or B cell lymphoma 38C13 were treated with a single dose of the conjugate (15, 25, and 75 mg Dox eq./kg i.v.) in a therapeutic regime. Anti-tumor resistance of the cured animals was proved by a second challenge with a lethal dose of tumor cells without additional treatment. RESULTS: The content of drug bound to the polymer is an important parameter in relation to the conjugate therapeutic efficacy. The best anti-tumor effects were produced by conjugates with 10 - 13 wt% of bound doxorubicin. Free doxorubicin up to 4.6% relative to total drug content had no impact on the treatment efficacy and acute toxicity. The conjugates induced a complete cure of mice and regular treatment-dependent development of specific anti-tumor resistance. No myelosuppression or organ damage was observed. CONCLUSIONS: A well-defined HPMA copolymer-doxorubicin conjugate with pH-sensitive drug release is a good candidate for clinical trials as it has remarkable anti-tumor efficacy and a favorable safety profile.
PURPOSE: In vivo efficacy and safety of HPMA-based copolymers armed with doxorubicin via a spacer containing pH-sensitive linkage that can be prepared within a broad range of attached drug contents (1) was tested in murinetumor models. METHODS:Mice bearing T cell lymphomaEL4 or B cell lymphoma 38C13 were treated with a single dose of the conjugate (15, 25, and 75 mg Dox eq./kg i.v.) in a therapeutic regime. Anti-tumor resistance of the cured animals was proved by a second challenge with a lethal dose of tumor cells without additional treatment. RESULTS: The content of drug bound to the polymer is an important parameter in relation to the conjugate therapeutic efficacy. The best anti-tumor effects were produced by conjugates with 10 - 13 wt% of bound doxorubicin. Free doxorubicin up to 4.6% relative to total drug content had no impact on the treatment efficacy and acute toxicity. The conjugates induced a complete cure of mice and regular treatment-dependent development of specific anti-tumor resistance. No myelosuppression or organ damage was observed. CONCLUSIONS: A well-defined HPMA copolymer-doxorubicin conjugate with pH-sensitive drug release is a good candidate for clinical trials as it has remarkable anti-tumor efficacy and a favorable safety profile.
Authors: B Ríhová; T Etrych; M Pechar; M Jelínková; M Stastný; O Hovorka; M Kovár; K Ulbrich Journal: J Control Release Date: 2001-07-06 Impact factor: 9.776
Authors: P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy Journal: Clin Cancer Res Date: 1999-01 Impact factor: 12.531
Authors: Gang Zhao; Rongguo Ren; Xin Wei; Zhenshan Jia; Ningrong Chen; Yuanyuan Sun; Zhifeng Zhao; Subodh M Lele; Haizhen A Zhong; Mary B Goldring; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2021-10-12 Impact factor: 9.776
Authors: Rui Zhang; Kui Luo; Jiyuan Yang; Monika Sima; Yongen Sun; Margit M Janát-Amsbury; Jindřich Kopeček Journal: J Control Release Date: 2012-12-20 Impact factor: 9.776
Authors: Martina da Ros; Anna Lisa Iorio; Maurizio Lucchesi; Alessia Stival; Maurizio de Martino; Iacopo Sardi Journal: Anticancer Agents Med Chem Date: 2015 Impact factor: 2.505